Wednesday, May 17, 2023 11:24:41 AM
However, I do respect and understand your right to disagree with me. But, I will have to go where the evidence takes me.
I am looking at the preponderance of the evidence, not just 1 speech in 2022. I believe that the advantages of using poly-ICLC as an in vivo maturation and activation agent, have been known by Dr. Liau, Dr. Prins, and the other members of the team at UCLA, since 2014, or even before. They will take this knowledge and move forward, not backwards.
Dr. Prins even showed us in 2016, in this graphical depiction below, that poly-ICLC is now automatically included as an in vivo maturation and activation agent when treating patients with DCVax-L:
Recent NWBO News
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
